Literature DB >> 19772931

SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo.

Li-Fei Hou1, Shi-Jun He, Jun-Xia Wang, Yang Yang, Feng-Hua Zhu, Yu Zhou, Pei-Lan He, Yu Zhang, Yi-Fu Yang, Ying Li, Wei Tang, Jian-Ping Zuo.   

Abstract

In the present study, we investigated the immunosuppressive effects and underlying mechanisms of beta-aminoarteether maleate (SM934), a derivative of artemisinin, against T cell activation in vitro and in vivo. In vitro, SM934 significantly inhibited the proliferation of splenocytes induced by concanavalin A (Con A), lipopolysaccharide (LPS), mixed lymphocyte reaction (MLR), and anti-CD3 plus anti-CD28 (anti-CD3/28). SM934 significantly inhibited interferon (IFN)-gamma production and CD4(+) T cell division stimulated by anti-CD3/28. SM934 also promoted apoptosis of CD69(+) population in CD4(+) T cells stimulated by anti-CD3/28. Furthermore, SM934 inhibited interleukin (IL)-2 mediated proliferation and survival through blocking Akt phosphorylation in activated T cells. In ovalbumin (OVA)-immunized mice, oral administration of SM934 suppressed OVA-specific T cell proliferation and IFN-gamma production. SM934 treatment also significantly inhibited the sheep red blood cell (SRBC)-induced delayed type hypersensitivity (DTH) reactions in mice. Taken together, SM934 showed potent immunosuppressive activities in vitro and in vivo. Our results demonstrated that SM934 might be a potential therapeutic agent for immune-related diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772931     DOI: 10.1016/j.intimp.2009.09.003

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  17 in total

Review 1.  Immune suppressive properties of artemisinin family drugs.

Authors:  Lifei Hou; Haochu Huang
Journal:  Pharmacol Ther       Date:  2016-07-10       Impact factor: 12.310

2.  Water-soluble artemisinin derivatives as promising therapeutic immunosuppressants of autoimmune diseases.

Authors:  Heng Li; Jianping Zuo; Wei Tang
Journal:  Cell Mol Immunol       Date:  2017-09-11       Impact factor: 11.530

3.  Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.

Authors:  Yanwei Wu; Shijun He; Bingxin Bai; Luyao Zhang; Lu Xue; Zemin Lin; Xiaoqian Yang; Fenghua Zhu; Peilan He; Wei Tang; Jianping Zuo
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

4.  Effect of Artemisia annua extract on treating active rheumatoid arthritis: A randomized controlled trial.

Authors:  Min Yang; Ming-Yang Guo; Yong Luo; Ming-Dong Yun; Jiao Yan; Tao Liu; Chang-Hong Xiao
Journal:  Chin J Integr Med       Date:  2016-12-29       Impact factor: 1.978

Review 5.  Artemisinin derivative SM934 in the treatment of autoimmune and inflammatory diseases: therapeutic effects and molecular mechanisms.

Authors:  Xiao Tong; Li Chen; Shi-Jun He; Jian-Ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2022-09-01       Impact factor: 7.169

Review 6.  Artemisinin and its derivatives: a potential therapeutic approach for oral lichen planus.

Authors:  Rui-Jie Ma; Ming-Jing He; Ya-Qin Tan; Gang Zhou
Journal:  Inflamm Res       Date:  2019-02-01       Impact factor: 4.575

Review 7.  Toll-like receptors: potential targets for lupus treatment.

Authors:  Yan-wei Wu; Wei Tang; Jian-ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

Review 8.  Qinghaosu (artemisinin): chemistry and pharmacology.

Authors:  Ying Li
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

9.  SM934 treated lupus-prone NZB × NZW F1 mice by enhancing macrophage interleukin-10 production and suppressing pathogenic T cell development.

Authors:  Li-Fei Hou; Shi-Jun He; Xin Li; Chun-Ping Wan; Yang Yang; Xiao-Hui Zhang; Pei-Lan He; Yu Zhou; Feng-Hua Zhu; Yi-Fu Yang; Ying Li; Wei Tang; Jian-Ping Zuo
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

10.  A novel tricyclic BTK inhibitor suppresses B cell responses and osteoclastic bone erosion in rheumatoid arthritis.

Authors:  Yu-Ting Liu; Hui-Hua Ding; Ze-Min Lin; Que Wang; Li Chen; Shuang-Shuang Liu; Xiao-Qian Yang; Feng-Hua Zhu; Yue-Teng Huang; Shi-Qi Cao; Fang-Ming Yang; Zi-Lan Song; Jian Ding; Mei-Yu Geng; Hua Xie; Ao Zhang; Shi-Jun He; Jian-Ping Zuo
Journal:  Acta Pharmacol Sin       Date:  2021-01-13       Impact factor: 7.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.